The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid and diabetes trials

Author:

Drexel Heinz1234,Rosano Giuseppe M C5,Lewis Basil S6,Huber Kurt78,Vonbank Alexander139ORCID,Dopheide Jörn F2,Mader Arthur139,Niessner Alexander10,Savarese Gianluigi11,Wassmann Sven1213,Agewall Stefan1415

Affiliation:

1. Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Academic Teaching Hospital Feldkirch, Carinagasse 47, 6800 Feldkirch, Austria

2. Division of Angiology, Swiss Cardiovascular Center, Freiburgstrasse 18, University Hospital Bern, 3010 Bern, Switzerland

3. Doctorate Studies Medical Science, Private University of the Principality of Liechtenstein, Dorfstrasse 24, 9495 Triesen, Principality of Liechtenstein

4. Drexel University College of Medicine, 2900 W Queen Ln, Philadelphia, PA 19129, USA

5. Department of Medical Sciences, IRCCS San Raffaele Hospital, Via della Pisana 235, 00163 Rome, Italy

6. Technion-Israel Institute of Technology, Ruth and Bruce Rappaport School of Medicine, Efron St 1, Bat Galim, 3525433 Haifa, Israel

7. 3rd Medical Department, Cardiology and Intensive Care Medicine, Wilhelminen Hospital, Montleartstraße 37, 1160 Vienna, Austria

8. Medical School, Cardiology, Sigmund Freud University, Campus Prater, Freudplatz 1, 1020 Vienna, Austria

9. Department of Medicine I, Academic Teaching Hospital Feldkirch, Carinagasse 47, 6800 Feldkirch, Austria

10. Department of Internal Medicine II, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria

11. Cardiology Unit, Department of Medicine, Karolinska Institute, Solnavägen 1, 171 77 Solna, Sweden

12. Cardiology Practice Pasing, Institutstraße 14, 81241 Munich, Germany

13. Medical Faculty, Clinical Medicine, University of the Saarland, Kirrberger Straße, 66421 Homburg, Germany

14. Department of Cardiology, Oslo University Hospital Ulleval, Kirkeveien 166, 0450 Oslo, Norway

15. Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Søsterhjemmet, Kirkeveien 166, 0450 Oslo, Norway

Abstract

Abstract Randomized clinical trials (RCTs) are important and the Gold Standard for drugs in modern cardiovascular (CV) therapy. The cornerstone of RCTs is the recording of hard clinical endpoints instead of surrogates. It is important to select an appropriate endpoint. Efficacy endpoints must be clinically relevant and can be hierarchically divided. A very interesting innovation in endpoint acquisition is the total event paradigm.

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3